Clinical trials: Digestive Neoplasms
Hepatocellular Carcinoma (HCC), Second Line Treatment
Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function
Open-label, single arm, multicenter phase II trial assessing the tolerability of a reduced starting dose of 40 mg cabozantinib for 4 weeks and subsequent dose escalation to 60 mg cabozantinib until disease progression or…
- Trial name
- NCT04522908
- Testing
- Cabozantinib Oral Tablet
- Where
- 10 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
HER2-expressing Cancers
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety…
- Trial name
- NCT03821233
- Testing
- ZW49
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 112 people
- Sponsor
- Zymeworks BC Inc.
Pancreatic Pseudocyst(s)
AXIOS Stent With Electrocautery Enhanced Delivery System
The purpose of this study is to demonstrate the safety and effectiveness of the AXIOS Stent with Electrocautery Enhanced Delivery System for endoscopic transenteric drainage of pancreatic pseudocysts.
- Trial name
- NCT02146352
- Testing
- AXIOS Stent with Electrocautery Enhanced Delivery System
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Xlumena, Inc.
dMMR/MSI-H-type Rectal Adenocarcinoma
The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)
Immunotherapy may bring revolutionary changes to the preoperative neoadjuvant treatment mode for dMMR/MSI-H locally advanced rectal cancer.
- Trial name
- Neo-IT (NCT07160647)
- Testing
- Ipalolimab and Tovorilimab
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sir Run Run Shaw Hospital
Hepatocellular Carcinoma, Metastasis
Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies
The purpose of this study is to evaluate the clinical feasibility and short-term outcome of switching monopolar RFA using a separable cluster electrode in patients with primary and secondary liver malignancies.
- Conditions
- Hepatocellular Carcinoma, Metastasis, Cholangiocarcinoma
- Trial name
- NCT02683538
- Testing
- Separable cluster electrode (Octopus®)
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Seoul National University Hospital
Esophageal Cancer
Quality of Life Outcomes Following Minimally Invasive and Open Esophagectomy for Esophageal Cancer
The goal of this study is to evaluate how surgery for esophageal cancer affects the patient's quality of life over time. The investigators hope this study will provide important information that can be used to improve the quality…
- Trial name
- NCT01558648
- Testing
- Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log
- Where
- United States
- Volunteers
- 257 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Patient Empowerment, Low Anterior Resection Syndrome
Interactive Online Informational and Peer Support App for Patients with Low Anterior Resection Syndrome
After surgery for rectal cancer, many people undergo changes in bowel habits, which may include the need to empty their bowels more often, accidental leakage of stool or gas, the sudden urge to go to the bathroom, and more.
- Conditions
- Patient Empowerment, Low Anterior Resection Syndrome, Colo-rectal Cancer, Peer Group
- Trial name
- NCT04469426
- Testing
- Interactive online informational and peer support app
- Where
- 5 sites in Canada
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Jewish General Hospital
Chemotherapy-induced Nausea and Vomiting, Colorectal Cancer
Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer
Addition of aprepitant, an NK1 receptor antagonist to a 5-HT3 receptor antagonist and dexamethasone regimen was shown to be effective for prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic…
- Trial name
- NCT02909478
- Testing
- Aprepitant+Tropisetron, Dexamethasone+Tropisetron
- Where
- China
- Volunteers
- 315 people
- Sponsor
- Sun Yat-sen University
Rectal Adenocarcinoma
A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma
This is a phase I study incorporating bavituximab into the care of patients with rectal adenocarcinoma simultaneously treated with capecitabine and radiation therapy.
- Trial name
- NCT01634685
- Testing
- Radiation, Bavituximab, Capecitabine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Texas Southwestern Medical Center
Rupture, Spontaneous, Rupture Liver
A Comparison Between Child-Pugh and Albumin-Bilirubin Scores
To compare Child-Pugh and Albumin-Bilirubin scores in patients with spontaneous rupture of hepatocellular carcinoma
- Conditions
- Rupture, Spontaneous, Rupture Liver, Hepatocellular Carcinoma, Hepatic Impairment
- Trial name
- NCT03534843
- Testing
- Liver resection, Transcatheter arterial embolization
- Volunteers
- 230 people
- Sponsor
- Huazhong University of Science and Technology
Esophageal Squamous Cell Carcinoma, Tislelizumab
Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC
This is a single institution and single-arm phase I/II study to assess the feasibility and efficacy of tislelizumab plus chemoradiation for conversion therapy of patients with locally nonresectable ESCC.
- Conditions
- Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation
- Trial name
- LATE (NCT05394415)
- Testing
- Tislelizumab, Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Colorectal Cancer
S0030: Capecitabine in Treating Older Patients W/Metastatic or Recurrent Colorectal Cancer That Cannot Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating older patients who have…
- Trial name
- NCT00049335
- Testing
- capecitabine
- Where
- 90 sites in United States
- Volunteers
- 29 people
- Sponsor
- SWOG Cancer Research Network
Hepatocellular Carcinoma
Observation Study: Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients
The purpose of this multicenter registry is to gather the safety, efficacy and survival data in intermediate and advanced HCC patients treated drug-eluting microsphere in Taiwan in order to provide clinical evidence in HCC…
- Trial name
- NCT03273608
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Metastatic Colorectal Cancer
An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to examine the correlation between UGT1A1 genotypes and the efficacy of CPT-11 based regimens (FOLFIRI, CPT-11+S-1, CPT-11) for patients with metastatic colorectal cancer.
- Trial name
- NCT01039506
- Testing
- CPT-11 based regimens
- Where
- Japan
- Volunteers
- 1,376 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Intrahepatic Cholangiocarcinoma (Icc)
An Exosomal miRNA-based Liquid Biopsy for ICC Detection
Intrahepatic cholangiocarcinoma (ICC) is a malignant liver tumor with poor prognosis and limited curative treatment options. Early and accurate detection remains an unmet clinical need.
- Trial name
- LUMIC (NCT07225452)
- Testing
- Small RNA sequencing, LUMIC assay
- Where
- United States
- Volunteers
- 535 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Gastric Cancer (GC), Sentinel Lymph Node Biopsy (SLNB)
Sentinel Lymph Node Detection in Gastric Cancer Using a Dual Tracer (Superparamagnetic Iron Oxide and Methylene Blue): A Prospective Study With Histological and OSNA Validation
Gastric cancer (GC) remains an oncological challenge, where lymph node involvement is a key prognostic factor. Sentinel lymph node (SLN) mapping may improve staging and reduce surgical morbidity.
- Trial name
- SLN_GC_SPIO (NCT07147452)
- Testing
- Dual tracer: The infiltration of the Supermagnetic Iron Oxide (SPIO) and Methylene Blue, OSNA AND H-E
- Where
- Spain
- Volunteers
- 44 people
- Sponsor
- Hospital del SAS de Jerez
Gastric Cancer
Consistency Between Treatment Responses in PDO Models and Clinical Outcomes in Gastric Cancer
Gastric cancer is the fourth leading cause of cancer-related death worldwide. Accurate assessment of the clinical responses to current treatment regimens is key to improving the prognosis and prolonging the survival of patients.
- Trial name
- NCT05203549
- Testing
- Tumor biopsy
- Where
- China
- Volunteers
- 250 people
- Sponsor
- D1 Medical Technology (Shanghai) Co., Ltd, China
Rectal Cancer, Chemotherapy Effect
Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Preoperative radiation with single agent chemotherapy as sensitizer is the standard care of locally advanced rectal cancer. Local irradiation significantly increases surgical complications and impairs quality of life.
- Trial name
- NCT03975049
- Testing
- Chemoradiation, FOLFOXIRI Protocol, Folfox Protocol
- Volunteers
- 933 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Metastatic Colorectal Cancer
Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.
The study is designed to analyze the pathological tumor response on resected colorectal cancer metastases after preoperative treatment with bevacizumab combined with FOLFOX or FOLFIRI regimen in a prospective cohort and to…
- Trial name
- BEV-ONCO2012 (NCT01858649)
- Testing
- Metastases resection, Bevacizumab, 5 FU
- Where
- 11 sites in Belgium
- Volunteers
- 60 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT07435038
- Testing
- BPI-572270
- Where
- 7 sites in Australia, China
- Volunteers
- 120 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.